Renown HIV specialist Dr. Gary
Blick Joins Immune Therapeutics Advisory
Board
Orlando, FL -- August 23,
2018 -- InvestorsHub NewsWire -- Immune Therapeutics, Inc.
(OTCQB:IMUN)
("Immune Therapeutics", "IMUN" or the "Company"), a late stage
clinical biopharmaceutical company
focused on the development of therapies for the treatment of autoimmune
diseases, inflammatory diseases, cancer and HIV/AIDS announced
today that Gary Blick MD will be joining the Immune
Therapeutics Scientific Advisory Board.
"We are pleased to welcome
Dr. Blick to our Scientific Advisory
Board. His extensive experience as a
treating HIV specialist and clinical researcher, along with his
immense knowledge of HIV complications, immune dysfunction,
regulatory procedures and drug development will greatly assist
Immune Therapeutics in our path to FDA approval of LDN for HIV patients,"
stated Noreen Griffin, President and CEO of Immune Therapeutics,
Inc.
Dr. Blick specializes in internal
medicine, HIV and sexually transmitted diseases. He headed his
private practice in Stanford Connecticut for over 30 years,
treating HIV
patients in the early days of the U.S. HIV epidemic. Dr.
Blick
is Founder of
Health Care Advocates International and BEAT AIDS Project Zimbabwe
where he serviced over 8600 patients. He received his Medical
degree at the University of Miami Miller School of Medicine,
performed his internship at Jackson Memorial Hospital and his
residency at Yale University School of Medicine. He has authored
over 40 publications and overseen numerous HIV clinical trials.
Dr. Blick is a member of the HIV
Medical Association, the
International Association of Providers of AIDS Care and a Member
and the American Academy of HIV Medicine.
"I am honored and very
exciting to join Immune Therapeutics' SAB. I have followed the
research on LDN from the early days of the HIV epidemic through its use on
the African continent, having reviewed the scientific data on its
use in Nigeria for presentation at the 2015 International
Conference on AIDS and STIs in Africa (ICASA) held in Zimbabwe. As
a unique immunomodulatory
agent that
is generally
well-tolerated in all patient types, its potential benefits for
people living with HIV/AIDS need to be fully explored, especially
in those with gastrointestinal co-morbidities, such as
Crohn's
enterocolitis,"
stated Dr. Blick.
HIV-related
gastrointestinal
complications effect a substantial number of the
1.2 million Americans presently living with HIV. Medications
for Crohn's disease and Irritable Bowel
Syndrome, two of the leading G.I. complications, have significant
potential adverse effects making them not optimal for
HIV patients suffering from HIV and GI co-indications. Immune
Therapeutics is focused on the study of LDN for this
population.
"I look forward to working
with Dr. Blick in our co- capacities of
Immune Therapeutics Scientific Advisory Board members.
Dr.
Blick's
prestigious
reputation in patient care and the study of HIV antiretroviral
medications, makes him an excellent addition to the Board," stated
Dr. Roscoe Moore, Chairman of the Board of Directors and Scientific
Advisory Board Member, Immune
Therapeutics, and Former U.S. Assistant Surgeon General.
Data presented at AIDS 2018,
and appearing in the June edition of HIV Plus Magazine, supports
LDN as a potential treatment for HIV patients presenting
significant
GI co-
morbidities such as irritable bowel syndrome
(IBS),
ulcerative
colitis (UC) and Crohn's Disease.
ABOUT IMMUNE
THERAPEUTICS, INC.
Immune Therapeutics, Inc. is
a late-stage biopharmaceutical company focused on the development
and commercialization of highly innovative immunotherapies. Immune
Therapeutics is actively developing T-Activation immunotherapies to
achieve immunomodulation in patients both human and pets with
autoimmune and inflammatory disease, cancer and infectious
diseases.
Forward-Looking Statements
This release may contain
forward-looking statements. Actual results may differ from those
projected due to a number of risks and uncertainties, including,
but not limited to, the possibility that some or all the matters
and transactions considered by the Company may not proceed as
contemplated, and by all other matters specified in the Company's
filings with the Securities and Exchange Commission. These
statements are made based upon current expectations that are
subject to risk and uncertainty. The Company does
not undertake to
update forward-looking statements in this news release to reflect
actual results, changes in assumptions or changes in other factors
affecting such forward-looking information. Assumptions and other
information that could cause results to differ from those set forth
in the forward-looking information can be found in the Company's
filings with the Securities and Exchange Commission (www.sec.gov),
including its recent periodic reports.
888-613-8802
http://www.immunetherapeutics.com/